What is the difference between Wellbutrin and Lexapro? They work on completely different neurotransmitter systems. Lexapro (escitalopram) is a selective serotonin reuptake inhibitor that increases serotonin, while Wellbutrin (bupropion) is a norepinephrine-dopamine reuptake inhibitor that affects dopamine and norepinephrine and has no meaningful effect on serotonin. That fundamental difference means they have different side-effect profiles, different FDA approvals, and different clinical uses, and it is why the choice between them is not arbitrary.
How Do Their Mechanisms of Action Differ?
Escitalopram works by blocking the serotonin transporter, which prevents serotonin from being reabsorbed after it is released into the synapse. The result is more serotonin available to bind to receptors, and over time that increased serotonin signaling is thought to improve mood and reduce anxiety. Escitalopram is highly selective for serotonin and has minimal effects on other neurotransmitter systems (Sanchez et al., 2014).
Bupropion inhibits the reuptake of dopamine and norepinephrine, not serotonin. According to the StatPearls review on bupropion, the drug acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects. Bupropion is the only currently available norepinephrine-dopamine reuptake inhibitor, and its dopamine activity is what makes it structurally and functionally distinct from SSRIs like escitalopram.
That difference in mechanism is not just pharmacological trivia. It determines which side effects occur, which conditions the medications work best for, and how a prescriber decides between them.
What Are the FDA-Approved Uses for Each?
Lexapro is FDA-approved for major depressive disorder and generalized anxiety disorder in adults (FDA label, Lexapro). The approval for anxiety is significant because it reflects a body of evidence showing that escitalopram reduces anxiety symptoms directly, not just as a secondary effect of treating depression.
Wellbutrin is FDA-approved for major depressive disorder and for the prevention of seasonal affective disorder (FDA label, Wellbutrin SR). Bupropion is also FDA-approved as an aid to smoking cessation, marketed under a different brand name but the same medication. It is not approved for anxiety, and in clinical practice it is generally avoided when anxiety is prominent, because its activating effects can worsen anxiety in some people.
If your main concern is depression with prominent anxiety, escitalopram's FDA approval for both conditions gives it an evidence advantage. If your main concern is depression with low energy or motivation, or if you are also trying to quit smoking, bupropion may be a better fit. If your diagnosis is generalized anxiety disorder without significant depression, escitalopram is the clear first-line choice.
How Do They Differ in Side Effects?
The side-effect profiles are strikingly different because the medications work on different neurotransmitter systems.
Sexual Side Effects
This is the most clinically significant difference. SSRIs like escitalopram commonly cause sexual side effects, including decreased libido, difficulty achieving orgasm, and erectile dysfunction in men. The mechanism is not fully understood, but elevated serotonin is thought to inhibit dopamine and norepinephrine pathways involved in sexual arousal and response.
Bupropion has a much lower rate of sexual dysfunction. In a randomized, double-blind study comparing bupropion extended release and escitalopram in adults with major depression, the incidence of orgasm dysfunction and worsened sexual functioning at week eight was statistically significantly lower with bupropion than with escitalopram (Clayton et al., 2006). A network meta-analysis of multiple studies found statistically significantly lower odds of sexual dysfunction with bupropion than with escitalopram, paroxetine, and sertraline.
If sexual side effects have been a problem with a prior SSRI, or if preserving sexual function is a high priority, that difference often drives the choice toward bupropion.
Weight and Appetite
Escitalopram can cause weight gain in some people, particularly with longer-term use. The mechanism is thought to involve serotonin's effects on appetite regulation and metabolism. Weight changes are unpredictable and do not happen to everyone, but they are common enough that prescribers ask about weight concerns during the evaluation.
Bupropion is more likely to cause decreased appetite and modest weight loss rather than weight gain, which is unusual among antidepressants. That effect is sometimes helpful for people who have gained weight on a prior SSRI, though it can be problematic for people who are underweight or have a history of eating disorders. According to the FDA label, bupropion is contraindicated in people with anorexia nervosa or bulimia, both because of the appetite suppression and because of the increased seizure risk in those populations.
Activation and Sedation
Bupropion is activating for most people, which means it can increase energy, focus, and motivation, but it can also cause restlessness, insomnia, and increased anxiety early in treatment. The FDA label notes that anxiety, nervousness, and insomnia are among the most commonly reported adverse reactions. For someone whose depression presents with low energy and oversleeping, that activation can be therapeutic. For someone whose depression is accompanied by anxiety and difficulty sleeping, it can be a problem.
Escitalopram is generally neither strongly sedating nor strongly activating, though individual responses vary. Some people find it mildly calming, which can be helpful if anxiety is prominent. Others experience restlessness or insomnia in the first few weeks, but those effects usually diminish as the body adjusts.
Other Side Effects
Both medications can cause nausea, headache, and dry mouth, particularly in the first few weeks. Escitalopram can cause sweating and tremor in some people. Bupropion can raise blood pressure slightly and has a dose-related risk of seizures, which is why the dose must be titrated carefully and why it is contraindicated in people with a seizure disorder.
Is One More Effective Than the Other for Depression?
The research suggests that both medications work well for major depression, and head-to-head comparisons have not shown a clear winner in overall effectiveness.
A 2023 study comparing fluoxetine, sertraline, and escitalopram found improvement rates above ninety percent for all three SSRIs, with no statistically significant differences in effectiveness for depression (Adjei et al., 2023). A 2016 systematic review and meta-analysis of bupropion as an antidepressant found that bupropion was as effective as SSRIs and other antidepressants for the acute treatment of depression, with no meaningful difference in response or remission rates (Patel et al., 2016).
Individual response varies widely, and someone who does not respond to one medication may respond well to the other. The reasons for that variability are not fully understood, but they likely involve differences in underlying neurobiology that are not captured by diagnosis alone. Effectiveness is one consideration, but side effects, tolerability, and specific symptom profile often matter more when choosing between medications with similar efficacy.
Why Is Bupropion Not Used for Anxiety?
Bupropion's effects on dopamine and norepinephrine make it activating, and that activation can worsen anxiety in people who are already anxious. The FDA label lists anxiety and nervousness as common adverse reactions, and the StatPearls review notes that anxiety disorders are a relative contraindication to bupropion use.
That does not mean bupropion is never used in people with anxiety. A 2025 systematic review found that in people with major depression and comorbid anxiety, bupropion was generally associated with improvements in anxiety symptoms alongside improvements in depression (Kamila et al., 2025). The key distinction is that the anxiety improved as the depression improved, not because bupropion was directly treating anxiety.
If anxiety is the primary concern, or if panic attacks are part of the picture, escitalopram is the safer and more evidence-backed choice. If depression is primary and anxiety is secondary, and if the anxiety is not severe, bupropion may still be an option, particularly if other factors favor it.
How Does a Prescriber Decide Between Them?
The decision is made during the evaluation based on your specific symptoms, past medication trials, medical history, and what side effects would be most problematic for you.
If generalized anxiety is prominent or the diagnosis is an anxiety disorder, escitalopram is usually the first choice. If depression is primary and anxiety is minimal, or if low energy and motivation are the main symptoms, bupropion may be preferred. If sexual side effects or weight gain have been problems with a prior SSRI, bupropion's lower risk in those areas might tip the scale. If insomnia is already a problem, escitalopram's less activating profile might be the safer starting point. If you have a seizure disorder or a history of an eating disorder, bupropion is contraindicated. If you are also trying to quit smoking, bupropion has the advantage of being FDA-approved for that use as well.
The evaluation is where those trade-offs get weighed, and the follow-up visits over the first two months determine whether the choice was the right one or whether a dose adjustment or switch is needed.
You can read more about when to consider medication for anxiety or depression if you are weighing whether to start a medication.
What If the First Medication Does Not Work?
A first medication not working does not mean medication will not help. Roughly half of people do not respond adequately to their first antidepressant, and that is a common outcome rather than evidence that nothing will work. The next step depends on what happened during the trial.
If there was no effect at all, a switch to a medication with a different mechanism might make sense. If you tried escitalopram and it did not work, switching to bupropion gives you a medication that works on entirely different neurotransmitter systems. If you tried bupropion and the depression did not improve, switching to an SSRI may be the better move. If there was a partial response, a dose increase or augmentation with a second medication might be more appropriate than switching. If side effects stopped the trial before it was complete, that is a different situation entirely.
Past medication trials are one of the most useful things you can bring to an evaluation, provided the details are clear: what was tried, at what dose, for how long, and what exactly happened. That information shapes the next step, and specificity matters more than you might think.
Getting Started
Laura Gabriel, PMHNP-BC, provides psychiatric evaluation and medication management for adults by secure telehealth video to people located in Connecticut, Massachusetts, New Hampshire, Maine, Rhode Island, Virginia, and Kentucky. The initial evaluation is where the choice between medications gets worked through, there is no obligation to start a medication at the first visit, and the conversation includes whether medication is the right step at all. Initial evaluations are typically $250–$350 before insurance reimbursement, and follow-up visits are $125–$200. You can learn more about how to get started as a new client or visit the insurance page for details on coverage and self-pay rates.
If you are in immediate danger, call 911. For urgent support at any hour, call or text 988 (Suicide & Crisis Lifeline). This article is general information, not medical advice, and is not a substitute for evaluation by a licensed clinician.
References
Adjei, K., Adunlin, G., & Ali, A. A. (2023). Impact of sertraline, fluoxetine, and escitalopram on psychological distress among United States adult outpatients with a major depressive disorder. Healthcare (Basel), 11(5), 740. https://pmc.ncbi.nlm.nih.gov/articles/PMC10001334/
Clayton, A. H., Croft, H. A., Horrigan, J. P., Wightman, D. S., Krishen, A., Richard, N. E., & Modell, J. G. (2006). Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. The Journal of Clinical Psychiatry, 67(5), 736–746. https://pubmed.ncbi.nlm.nih.gov/16841623/
Kamila, K., Suleiman, A. K., & McCabe, C. (2025). Efficacy and tolerability of bupropion in major depressive disorder with comorbid anxiety symptoms: A systematic review. Journal of Psychopharmacology, 39(2), 115–127. https://pubmed.ncbi.nlm.nih.gov/41465198/
Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. (2016). Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Therapeutic Advances in Psychopharmacology, 6(2), 99–144. https://pmc.ncbi.nlm.nih.gov/articles/PMC4837968/
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014). A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? International Clinical Psychopharmacology, 29(4), 185–196. https://pmc.ncbi.nlm.nih.gov/articles/PMC4047306/
U.S. Food and Drug Administration. (2023). LEXAPRO (escitalopram oxalate) tablets, for oral use [Label]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13bb8267-1cab-43e5-acae-55a4d957630a
U.S. Food and Drug Administration. (2023). WELLBUTRIN SR (bupropion hydrochloride) sustained-release tablets, for oral use [Label]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cbc8c074-f080-4489-a5ae-207b5fadeba3
U.S. National Library of Medicine. (2024). Bupropion. In StatPearls. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/sites/books/NBK470212/